FAST NEWS: Henlius expects first-ever annual profit on strong drug sales
The latest: Shanghai Henlius Biotech Inc. (2696.HK) said on Monday it expects to report a net profit of 500 million yuan ($69.5 million) or more for 2023, reversing a loss of 695 million…
FAST NEWS: Henlius swings to the black on strong sales growth
The latest: Shanghai Henlius Biotech Inc. (2696.HK) on Wednesday reported a net profit of 408 million yuan ($56.2 million) in the first three quarters of this year, reversing a loss of…
FAST NEWS: Henlius Biotech’s revenue doubles in first quarter
The latest: Shanghai Henlius Biotech Inc. (2696.HK) reported its revenue soared 97.2% to 996 million yuan ($145 million) in the first quarter, according to a business update released on Sunday.…
FAST NEWS: Henlius Biotech’s annual sales double, but loss widens in second half
The latest: Shanghai Henlius Biotech Inc. (2696.HK) reported last Friday its revenue soared 91.1% to 3.21 billion yuan ($466 million) last year, while its annual net loss narrowed 29.4% to…
Recent Articles
RELATED ARTICLES
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK -
ECARX reports its first profit, expects added revenue from Volkswagen tie-up
ECX.US
-
Fosun moves on from debt crisis with renewed focus on tourism, healthcare
0656.HK
-
NaaS drives into third quarter with first-ever quarterly non-IFRS profit
NAAS.US
-
Leapmotor jumps to first-ever quarterly profit
9863.HK
-
NEWS WRAP: VNET records first annual profit in three years
VNET.US
-
Baozun returns to the black as Gap expansion accelerates
9991.HK BZUN.US
